Medtronic reports positive real-world data for Melody TPV

Medtronic has announced positive data from a one-year real-world study of its Melody transcatheter pulmonary valve (TPV).

The device, which was first approved by the US Food and Drug Administration in 2010, has been used to treat 6,000 patients worldwide to date, with more than half being children with congenital heart disease.

In a US post-approval study, the TPV was shown to be associated with high procedural success, excellent valve function and few repeat procedures at the primary endpoint of six months.

Its headline success rate was 98 percent, while nearly all patients were free from major stent fracture, transcatheter pulmonary valve dysfunction and reintervention after half a year.

Dr John Liddicoat, senior vice-president at Medtronic and president of its structural heart business, said: "The Melody TPV is making a big difference in the lives of these young patients and we're committed to continuing to provide successful therapies for this underserved patient group."

This comes after the company also recently reported positive data from a global registry showing the safety benefits offered by its Symplicity renal denervation system.